Search This Blog

Thursday, January 2, 2020

DermTech up 13% premarket on Medicare coverage of PLA test

Thinly traded micro cap DermTech (NASDAQ:DMTK) is up 13% premarket on light volume in reaction to its announcement that Medicare has finalized reimbursement for its Pigmented Lesion Assay (PLA) as an aid to rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more clinical or historical characteristics suggestive of melanoma.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.